Ascendis Pharma A (ASND) Amortizatization of Intangibles (2021 - 2025)
Ascendis Pharma A (ASND) reported Amortizatization of Intangibles of $150161.6 for Q4 2025, up 18.09% on a YoY basis from $127162.9 in Q4 2024, and up 4.43% sequentially from $143793.8 in Q3 2025.
Ascendis Pharma A (ASND) Amortizatization of Intangibles (2021 - 2025) Analysis & Trends
Ascendis Pharma A (ASND) has 5 years of Amortizatization of Intangibles data on file, last reported at $150161.6 in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles rose 18.09% year-over-year to $150161.6; the trailing twelve-month figure through Dec 2025 stood at $553832.8 (up 9.56% YoY), and the FY2025 full-year result was $570381.3, up 12.85% from the prior year.
- Amortizatization of Intangibles advanced to $150161.6 in Q4 2025, from $143793.8 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $161391.0 in Q4 2023 to a low of $111918.5 in Q3 2022.
- A 5-year average of $128817.0 and a median of $126729.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 42.51% in 2023 and decreased 21.21% in 2024, its largest moves.
- Tracing ASND's Amortizatization of Intangibles over 5 years: stood at $128124.7 in 2021, then fell by 11.61% to $113247.5 in 2022, then jumped by 42.51% to $161391.0 in 2023, then decreased by 21.21% to $127162.9 in 2024, then advanced by 18.09% to $150161.6 in 2025.
- Business Quant data shows ASND's Amortizatization of Intangibles at $150161.6 in Q4 2025, $143793.8 in Q3 2025, and $134703.2 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 3.22 Mn |
| 10 | Ascendis Pharma A | 15.35 Bn | 14.68 Bn | 268.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 150,161.61 |
| Dec 31, 2025 | 150,161.61 |
| Sep 30, 2025 | 143,793.78 |
| Sep 30, 2025 | 143,793.78 |
| Jun 30, 2025 | 134,703.20 |
| Jun 30, 2025 | 134,703.20 |
| Mar 31, 2025 | 125,174.25 |
| Mar 31, 2025 | 125,174.25 |
| Dec 31, 2024 | 127,162.85 |
| Dec 31, 2024 | 127,162.85 |
| Sep 30, 2024 | 126,295.24 |
| Sep 30, 2024 | 126,295.24 |
| Jun 30, 2024 | 123,842.07 |
| Jun 30, 2024 | 123,842.07 |
| Mar 31, 2024 | 128,190.69 |
| Mar 31, 2024 | 128,190.69 |
| Dec 31, 2023 | 161,390.99 |
| Dec 31, 2023 | 161,390.99 |
| Sep 30, 2023 | 120,833.54 |
| Sep 30, 2023 | 120,833.54 |